Athira Pharma
Athira Pharma develops novel small molecule therapies for diseases with limited treatment options, including metastatic breast cancer and ALS. Its lead drug candidates are lasofoxifene and brelgometon (ATH-1105), which are evaluated in clinical trials to improve care for patients through innovative research and product development.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Pharmaceuticals
- Employees
- 70
Is this your organization? Claim it
EIT Pharma, led by ex-Athira CEO Leen Kawas, raises $35M Series A to advance lonafarnib for chronic hepatitis D
Kirkland-based EIT Pharma, led by former Athira CEO Leen Kawas, raised $35 million in an oversubscribed Series A led by Propel Bio Partners to support FDA review, manufacturing and commercial preparations for lonafarnib as an oral treatment candidate for chronic hepatitis D. The FDA accepted EIT Pharma's New Drug Application for lonafarnib on Aug. 11; the drug was acquired from Eiger BioPharmaceuticals' 2024 bankruptcy sale.
Nautilus Biotechnology Lays Off 16% of Staff, Postpones Proteome Platform Launch to Late 2026
Nautilus Biotechnology laid off 16% of its workforce to extend its cash runway into 2027 and delayed the commercial release of its proteome analysis platform until late 2026. The company aims to control operating expenses and maximize its impact on biological science, focusing on proteomics to advance drug development.
Athira Pharma Lays Off 70% of Workforce, Cuts $13.4M Annually Amid Failed Alzheimer’s Trial and Restructuring
Seattle-based biotech Athira Pharma is laying off 49 employees, about 70% of its workforce, as part of restructuring and cost-cutting after unsuccessful Phase 2/3 trial results. The company aims to focus on its ALS treatment ATH-1105 and expects to save $13.4 million annually, with leadership changes effective October 1.
People
-
Rachel Lenington Executive, Chief Operating Officer and Chief Development Officer
